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Retinitis pigmentosa is a clinical and genetic group of inherited retinal disorders characterized by alterations of photoreceptors and
retinal pigment epithelium leading to a progressive concentric visual field restriction, which may bring about severe central vision
impairment. Haemodynamic studies in patients with retinitis pigmentosa have demonstrated ocular blood flow abnormalities
both in retina-choroidal and in retroocular vascular system. Moreover, several investigations have studied the augmentation of
endothelin-1 plasma levels systemically in the body and locally in the eye. This might account for vasoconstriction and ischemia,
typical in vascular dysregulation syndrome, which can be considered an important factor of reduction of the ocular blood flow in
subjects affected by retinitis pigmentosa.
1. Introduction
Recent studies have observed the reduced blood flow in both
ocular and peripheral districts in patients suffering from
retinitis pigmentosa (RP) [1]. The drop of the blood flow has
been detected not only in retinal and choroidal vessels but
also in retroocular vessels [2–4]. Also, a reduced baseline
peak flow in the cutaneous capillary of fingers has been
measured and a significantly longer recovery time has been
found after cold provocation [4]. In the early stages of RP
before detecting any ophthalmoscopic fundus modification,
an increase of the arteriovenous passage time has been
observed in the retina [5]. Using colour Doppler imaging,
Cellini and coworkers demonstrated reduced peak systolic
velocities in both ophthalmic arteries and posterior ciliary
arteries [3, 4]. They also observed a certain augmentation
of endothelin-1 (ET-1) plasma levels in patients with early-
stage RP, even though some investigators took issue with this
observation [6–8].
A sort of dysregulation of both blood supply and vessel
caliber seems to occur often in RP patients. Konieczka has
suggested that the primary vascular dysregulation syndrome,
mainly characterized by an impaired vascular tone, might
describe a wide range of local and systemic signs, such as
ocular blood flow reduction with subsequent augmentation
of ET-1 plasma levels in the eye and peripheral vasospasm in
response to cold, emotional stress, or low blood pressure [1,
9–13]. Disturbed autoregulation of ocular perfusion provokes
an irregular blood flow, which means an unstable retinal
blood supply, and a sort of attenuation of retinal vessels
with reduced neurovascular coupling [14, 15]. Consequently,
both free radicals and oxidative stress substantially increase.
Therefore, a large number of RP patients show a high
prevalence of primary vascular dysregulation syndrome as
the primary manifestation of ocular blood flow dysfunction
[1]. Even if the exact pathophysiological mechanism is still
unknown, the dysfunction of both autonomic nervous system
and endothelial cells is currently investigated.
2. A Brief Overview of Retinitis Pigmentosa
RP is a clinical and genetic group of inherited retinal disor-
ders. It is characterized by alterations of photoreceptors (PRs)
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and retinal pigment epithelium (RPE) resulting in progressive
retinal degeneration.Themost frequent symptoms are night-
blindness and the growing impairment of visual field, per-
ceived as tunnel vision, thatmay lead to legal blindness. Clini-
cal signs found at ophthalmic fundus examination are charac-
teristic: “bone-spicule” pigment deposits in the mid periph-
ery along with RPE atrophy, attenuation of retinal vessels,
waxy pallor of the optic disc, and relatively spared macula
surrounded by a perimacular ring of depigmentation [16, 17].
The age of onset, the rate of progression, and the severity
of RP are extremely variable depending not only on the
genetic background but also on some influencing factors.
Symptoms may start in childhood as well as in the early or
mid-adulthood. Even though the progression of the disease
is unpredictable, severe visual impairment typically occurs by
the age of about 40–50 years. The prevalence of all different
forms of RP is reported to be about 1 : 3500–5000 individuals
and, nowadays, it is estimated that there are almost two
million affected people around the world [18, 19].
The group of RP is characterized by a complex association
between tremendous genotypicmultiplicity and great pheno-
typic heterogeneity. The severity of the clinical manifestation
depends on the penetrance of the disease gene, but also inter-
actions between the gene expression and the environmental
factors are of great importance [20].
3. The Ocular Blood Flow
The blood flow in the body is fine-tuned both systemically
and locally. Specific biochemical and molecular signaling
pathways keep monitoring the perfusion pressure, originally
controlled by the heart pump, and the local resistances,
depending on the vessel caliber. Vasospasm stands for inap-
propriate constriction of an artery [21]. In the presence of
excessive vasoconstriction and/or altered vasodilation, the
overall condition is described as vascular dysregulation and
it is often accompanied by a barrier dysfunction. If this
condition is associated with symptoms or signs, it is referred
to as vascular dysregulation syndrome. It can affect any
district in the body but mostly the eye [22].
The diameter of the vessels is regulated by contrac-
tion (vasoconstriction) or relaxation (vasodilation) of both
smooth muscle cells, forming the arterial or venous wall,
and pericytes, encircling the capillaries. The smooth muscle
cells are very sensitive to modifications of tension (myogenic
regulation), numerous metabolic factors originating from
surrounding tissues, and biochemical signals coming from
the autonomic nervous system (neurohumoral regulation)
[23]. The local perfusion pressure, depending on the cardiac
output, and the local resistance to flow, depending on the rate
of local autoregulation, are the two main aspects of the tissue
blood flow.
The endothelium is a very thin layer of cells lining vessels
inwards. Beyond its function as mechanical barrier, it plays
crucial roles in immune and inflammatory responses, in
haemostasis, and in vascular tone regulation. Also it has
autocrine, paracrine, and endocrine functions [24, 25].
Two vascular systems supply the eye: the choroidal and
the retinal system. The first supplies the iris, the ciliary body,
the choroid, and also, by diffusion, the outer retina, including
the photoreceptors. The second entirely supplies the inner
retina, comprising the retinal ganglion cells. The retinal
vascular network is characterized by low perfusion rate, high
vascular resistance, and high oxygen extraction. Conversely,
the choroidal network shows a high perfusion rate, a low
vascular resistance, and a low oxygen extraction. Just similar
to the brain circulation, the ocular circulation is autoregu-
lated. Autoregulation, actually effective within certain limits
of perfusion pressure, is the intrinsic capacity to maintain
constant flow despite changes in perfusion pressure [26].
The neurovascular coupling is the tight link between the
caliber of retinal vessels and the neuroretinal activity. A signal
from the central nervous system, closely connected to the
retina, is able to evoke small changes in the retinal blood
flow through complex pathways involving neurons, glia, and
endothelial cells. Furthermore, the retinal vascular system
features the blood retinal barrier which regulates the flux
of ions, proteins, hormones, and water, even monitoring the
infiltration of immune competent cells [22]. The choroidal
vascular system is richly innervated [27]. It provides oxygen
and other metabolites, controls eye temperature, and mostly
contributes to the fine-tuning of accommodation by regulat-
ing choroidal thickness. This network, featuring fenestrated
capillaries, is just partially autoregulated [22].
4. The Endothelin System
The endothelin (ET) system encompasses three active pep-
tides (ET-1, ET-2, and ET-3), twoGprotein-coupled receptors
(ETA and ETB), and activating peptidases including the ET-
converting enzymes (ECE-1 and ECE-2), [28]. Knock-out
mice have been used as models to study pathophysiological
role of the ET system. Some ET components are essential
for the development of both tissues, such as cardiac or
craniofacial tissue, and systems, such as enteric and nervous
system [29–31]. Endothelin-1 (ET-1), widely distributed in
human tissues, is produced by vascular endothelial cells and
also by many other cells. Endothelin-2 (ET-2), with equally
high affinities for both ETA and ETB, is largely expressed
in the gastrointestinal tract and it serves as local and
paracrine/autocrine mediator [32]. Very little is known about
the function of endothelin-3 (ET-3), except for the fact that it
seems to be secreted somewhere near the relevant target cells,
such as enteric neuroblasts expressing the ETB [33].
First identified in 1988, ET-1 is themost powerful endoge-
nous vasoconstrictor of both small and large vessels [34, 35].
It is a peptide with 21 amino acid residues and it is mostly
released by endothelial cells of arteries, veins, and lymphatic
vessels [36]. ET-1 acts as amodulator of the secretion of renin,
vasopressin, and aldosterone, but at the same time it inhibits
platelet aggregation [37]. Stressful conditions elicit increasing
plasma levels of ET-1. Indeed, it has been observed in patients
suffering with high blood pressure, arteriosclerosis, acute
myocardial infarction, and diabetes mellitus [38–41]. Also
hypoxic or oxidative stress, systemically and locally, has been
identified as strong stimulus to raise primarily the levels
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of hypoxia-inducible factor 1 (HIF-1) and subsequently the
levels of ET-1. In the eye, local synthesis and secretion of
ET-1 are performed by many tissues, such as cornea, uveal
tissue, retinal microvascular pericytes, RPE cells, and optic
nerve, suggesting that the ET system could have an important
role in the pathophysiology of some eye diseases [42–46].
Glaucoma, diabetic retinopathy, retinal vein/artery occlusion,
proliferative vitreoretinopathy, and inherited retinal dystro-
phies are featured by impaired ocular blood circulation and
they all present abnormal ET-1 plasma levels [47–51].
ET-2 is a protein encoded by the endothelin-2 gene
(EDN2) and is a member of the ET system. It is referred to
as macrophage chemoattractant and it is strongly induced
in PRs in the course of retinal diseases and injury, being
involved as stress signal to Müller cells through ETB [52,
53]. Supposedly, a wide range of retinal disorders, including
the inherited retinal dystrophies such as RP, converge on a
relatively small number ofmolecular pathways going towards
the cellular repair or death [54]. Müller cells, the most
abundant glial cells in the retina, seem to monitor the
status of retinal neurons, being generally activated after PRs’
degeneration or death [55, 56]. There is evidence that injured
or degenerated PRs start to release ET-2 stimulating the
activation of the Müller cells fitted with ETB. These glial cells
increase both the production of glial fibrillary acidic protein
and the sensitivity to ET-2 by upregulating the ETB as part of
their repairing response [53, 57].
5. ET-1 Blood Levels in Retinitis Pigmentosa
ET-1 can be used as biochemical marker to assess ocular
hemodynamics. To measure intraocular ET-1 blood concen-
tration, colourDoppler imaging and laser Doppler flowmetry
have been the two techniques specifically employed. Inves-
tigations showed the significant correlation between ET-1
plasma choroidal and plasma systemic concentrations [3].
In cases of RP, Cellini and coworkers have reported that
a general increase in plasma levels of ET-1 elicits vasocon-
striction both systemically and locally in the eye, causing
retinal and choroidal hemodynamic impairment involving
both ophthalmic artery and posterior ciliary arteries [2, 5,
6, 58, 59]. The role of the ET system in the pathogenesis of
several ocular diseases, including the RP, is unquestionably
important. However, at present there are some discordant
studies about ET-1 plasma levels in people suffering from
inherited retinal dystrophies. Cellini and colleagues have
repeatedly observed high concentrations of ET-1 in these
patients, whereas Ohguro and colleagues reported low levels
of ET-1 [3, 8, 51, 60]. Regardless of their opposite experimental
observations, common evidence is the decreased intraocular
blood flow, initially in both choroid and optic nerve head and
later in retina, due to abnormal plasma levels of ET-1 [61, 62].
A proper biochemical pathway responsible for the
reduced intraocular blood flow is still not ascertained;
however, there are some hypotheses under investigation.
The first is about the migration of RPE cells to the inner
layers of the retina after PRs’ death. Local secretion of ET-1
from the proliferated and migrated RPE cells may stimulate
repairing processes by deposition of extracellular matrix
Table 1: The local and systemic increase of ET-1 and the vascular
dysregulation syndrome in RP.
Drop in ocular blood flow
(i) Altered vessel caliber








(iv) Biochemical and metabolic
alterations of retinochoroidal
endothelial cells
Degeneration of PRs (i) Chronic oxidative stress
(ii) Subclinical inflammation
ET-1: endothelin-1; RP: retinitis pigmentosa; PRs: photoreceptors.
just underneath the retinal vessels [46]. As a consequence,
thinning and fenestration of retinal vascular endothelial cells
occur [63].The second assumption considers the fact that the
more the PRs die the less the ocular blood supply is required.
Thus, a sort of vascular remodeling takes place in the chori-
oretinal tissue [64]. Another aspect to take into consideration
is the low oxygen consumption by the degenerated and dying
PRs.The subsequent vasoconstriction,mediated by increased
levels of ET-1, is referred to as mechanism for limiting higher
oxygen levels locally [65, 66]. Table 1 supplies a brief and clear
summary of the crucial role of ET-1 in RP.
On the basis of recent investigations, in subjects with
RP there is a statistically significant correlation between the
augmentation of ET-1 plasma levels and the drop of the
peak systolic velocity in both the ophthalmic artery and
the posterior ciliary arteries [51]. The genetics are definitely
remarkable, but the impaired retinochoroidal blood supply
might be considered as an important modifier of the progres-
sive loss of PRs. Furthermore, a sort of systemic dysfunction
of the microcirculation seems to be in people with RP. In
fact, Cellini and coworkers have measured, by means of
laser Doppler flowmetry, a lower baseline cutaneous capillary
blood flow and a longer warm recovery time in RP patients
with respect to healthy subjects [3]. It has been observed that
biochemical andmetabolic alterations of the endothelial cells
of retinal vessels and the augmentation of the intraocular
oxygen concentration are triggering factors for the retinal
production of ET-1. This molecule provokes high levels of
intracellular Ca2+ in glial and neuronal cells and increases
both neuronal activities and neuronal responses to glutamate
[67]. Also, through ETA receptors ET-1may have a synergistic
effect on the glutamate-induced neurotoxicity in the retina
[68]. Other studies have also highlighted the pivotal role of
ET-1 in relation to the apoptosis of the retinal ganglion cells
through ETB receptors [69].
6. Conclusions
To date, big efforts are still to be made to assess a fine corre-
lation between genetic mutations and clinical manifestations
in the RP. The most of mutations occur in genes coding for
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proteins involved in the cycle of vision, at the level of rods,
cones, and RPE cells [1]. In the course of the disease, the
PRs go towards apoptosis, so that the outer retinal nuclear
layer flattens [70]. The pigment deposits, described as bone-
spicule pigmentation, result from both RPE cell degeneration
and migration into the neural retina after PRs’ death [71].
There is evidence that oxidative stress and related conditions
play an important role in the inherited retinal dystrophies
[72]. Another important aspect of RP is the reduced blood
flow in both ocular and peripheral districts along with a
substantial increase in levels of inflammation [1, 22]. Strobbe
and coworkers demonstrated a statistically significant corre-
lation between ocular inflammation, detected by measuring
aqueous flare with the noninvasive laser flare-cell meter, and
high ET-1 plasma levels in patients suffering from RP [60].
This condition features alterations in choroidal thickness and
blood flow leading to a boost in free radicals and oxidative
stress.
Several general conditions, such as hypoxia, chronic
oxidative stress, vascular dysregulation, or systemic inflam-
mation, provoke the increase of ET-1 plasma levels. This
molecule acts as powerful vasoconstrictor resulting in drop
of the blood flow. This aspect is well-recognized in patients
with RP who have low and impaired ocular blood flow, also
characterized by progressive choroidal thinning and atten-
uation of retinal vessels. Some authors have observed that
RP subjects feature an imbalance of the antioxidant-oxidant
status in the peripheral blood [73]. Thus, the subclinical
general inflammation and the substantial oxidative stress
trigger the production of high levels of ET-1, which in turn
bring about vascular dysregulation and diffuse hypoxic stress.
This vicious circle contributes to activating and amplifying
the inflammatory response. In the eye, vasospasm and altered
intraocular perfusion bring about relative ischemia and, as a
consequence, degeneration of the PRs [60].
Further investigations are needed to confirm the link
between vascular dysregulation and subclinical inflammation
in RP. However, in the next future research probably focuses
on the development of novel drugs as antagonists of ET-1
and new antioxidants in order to better improve the vascular
function systemically as well as locally.
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“Endothelium-dependent vasoactive modulation in the oph-
thalmic circulation,” Progress in Retinal and Eye Research, vol.
20, no. 2, pp. 209–225, 2001.
[26] J. Flammer and M. Mozaffarieh, “Autoregulation, a balancing
act between supply and demand,” Canadian Journal of Ophthal-
mology, vol. 43, no. 3, pp. 317–321, 2008.
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